RESUMO
OBJECTIVES: Autoantibodies directed against cytosolic 5'-nucleotidase 1A have been identified in many patients with inclusion body myositis. This retrospective study investigated the association between anticytosolic 5'-nucleotidase 1A antibody status and clinical, serological and histopathological features to explore the utility of this antibody to identify inclusion body myositis subgroups and to predict prognosis. MATERIALS AND METHODS: Data from various European inclusion body myositis registries were pooled. Anticytosolic 5'-nucleotidase 1A status was determined by an established ELISA technique. Cases were stratified according to antibody status and comparisons made. Survival and mobility aid requirement analyses were performed using Kaplan-Meier curves and Cox proportional hazards regression. RESULTS: Data from 311 patients were available for analysis; 102 (33%) had anticytosolic 5'-nucleotidase 1A antibodies. Antibody-positive patients had a higher adjusted mortality risk (HR 1.89, 95% CI 1.11 to 3.21, p=0.019), lower frequency of proximal upper limb weakness at disease onset (8% vs 23%, adjusted OR 0.29, 95% CI 0.12 to 0.68, p=0.005) and an increased prevalence of excess of cytochrome oxidase deficient fibres on muscle biopsy analysis (87% vs 72%, adjusted OR 2.80, 95% CI 1.17 to 6.66, p=0.020), compared with antibody-negative patients. INTERPRETATION: Differences were observed in clinical and histopathological features between anticytosolic 5'-nucleotidase 1A antibody positive and negative patients with inclusion body myositis, and antibody-positive patients had a higher adjusted mortality risk. Stratification of inclusion body myositis by anticytosolic 5'-nucleotidase 1A antibody status may be useful, potentially highlighting a distinct inclusion body myositis subtype with a more severe phenotype.
Assuntos
5'-Nucleotidase/imunologia , Autoanticorpos/sangue , Fibras Musculares Esqueléticas/patologia , Miosite de Corpos de Inclusão/sangue , Miosite de Corpos de Inclusão/diagnóstico , Idade de Início , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Citosol , Complexo IV da Cadeia de Transporte de Elétrons/análise , Feminino , Humanos , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Fibras Musculares Esqueléticas/química , Debilidade Muscular/etiologia , Miosite de Corpos de Inclusão/patologia , Prognóstico , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Tecnologia Assistiva/estatística & dados numéricos , Taxa de Sobrevida , Fatores de TempoRESUMO
BACKGROUND: Acute exacerbations are a characteristic clinical expression of chronic obstructive pulmonary disease (COPD). The objective of this study was to investigate the occurrence rate, management, and healthcare costs of exacerbations in patients with COPD in Dutch general practice. METHODS: Baseline data set from the COPD on Primary Care Treatment (COOPT) trial was used. Details on the occurrence and management of exacerbations were collected by systematic medical record review for the 2-year period preceding trial inclusion. RESULTS: The mean age of the 286 study subjects involved was 59.2 (SD 9.6) years, postbronchodilator FEV1 67.1% (SD 16.2) of predicted. Following ERS criteria, subjects suffered from: no (26%); mild (19%); moderate (40%); or severe (15%) airflow obstruction. The overall mean and median annual exacerbation rates were 0.88 (SD 0.79) and 0.5 (IQR 1.0), respectively. Exacerbation rate was not related to severity of airflow obstruction (p=0.628). Mean annual exacerbation costs per subject were 40 Euro, 53 Euro, 61 Euro and 92 Euro for the respective severity subgroups (p=0.012). The increase of costs in the more severe subgroups was mainly attributable to more physician consultations, diagnostic procedures, and prescription of reliever medication (e.g., bronchodilators, cough preparations). CONCLUSIONS: Occurrence of exacerbations did not depend on the severity of airflow obstruction, whereas the healthcare cost associated with exacerbations increased along with the severity of the disease.
Assuntos
Custos de Cuidados de Saúde , Doença Pulmonar Obstrutiva Crônica/economia , Idoso , Análise de Variância , Antitussígenos/uso terapêutico , Broncodilatadores/uso terapêutico , Distribuição de Qui-Quadrado , Tosse/tratamento farmacológico , Coleta de Dados , Medicina de Família e Comunidade , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Países Baixos , Doença Pulmonar Obstrutiva Crônica/classificação , Doença Pulmonar Obstrutiva Crônica/diagnóstico , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Doença Pulmonar Obstrutiva Crônica/fisiopatologia , Ensaios Clínicos Controlados Aleatórios como Assunto , Testes de Função Respiratória , Estações do AnoRESUMO
This prospective study conducted in the Holy Family Municipal Hospital in Techiman, Ghana aimed to determine the incidence of wound infection following internal fixation of closed fractures in a municipal hospital in a developing country. Between May 2000 and February 2005, 194 patients were treated for closed fractures, implanting a total of 215 internal fixations. Patients were reviewed 10, 30 and 120 days after operation. In 141 (73%) patients, a follow-up of four months was achieved. Of all patients, six developed an infection, two deep and four superficial. The cumulative incidence of wound infection after internal fixation was 3.3%. This study demonstrates that the incidence of wound infection following internal fixation is comparable with hospitals in a temperate climate in industrialized countries. We therefore conclude that specific tropical risk factors play a minimal role in the development of wound infection.